Connection

Fengcai Zhu to Age Factors

Back to Details
This is a "connection" page, showing publications Fengcai Zhu has written about Age Factors.
Fengcai Zhu
Connection Strength
0.164
Age Factors
  1. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
    View in: PubMed
    Score: 0.047
  2. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 10; 8(14):6195-6211.
    View in: PubMed
    Score: 0.044
  3. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. Expert Rev Vaccines. 2018 03; 17(3):257-262.
    View in: PubMed
    Score: 0.039
  4. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17; 361(25):2414-23.
    View in: PubMed
    Score: 0.022
  5. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 08; 285:198005.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.